Third Rock Ventures Sells $17.2 Million in Rapport Therapeutics Shares Amid 230% Stock Surge
Third Rock Ventures, a 10% shareholder of Rapport Therapeutics (RAPP), sold 426,005 shares valued at $17.18 million on April 17, 2026. The sale occurred after RAPP's stock surged 230% over the past year, with Phase 3 trials nearing. The transaction was part of a pre-scheduled trading plan and did not significantly alter the insider's overall ownership stake.
Topics: insider selling Phase 3 trials SEC filings stock price movement